Protein chip maker Zyomyx of Hayward, Calif., has entered into an agreement for access to BD Biosciences antibody collection, Zyomyx said.
Under the terms of the deal, Zyomyx will have access to BD Biosciences antibodies for use in protein biochip development. BD Biosciences will also develop other antibodies exclusively for Zyomyx. The companies did not disclose financial specifics of the agreement.
BD Biosciences already has a catalog of many thousands of antibodies, which have been selected and validated over the years to commercially relevant and interesting targets, said Lawrence Cohen, CEO of Zyomyx. The deal not only gives us access to their catalog, but also a collection of new antibodies that they continue to expand on.
Zyomyx is currently developing chips designed to detect up to 10,000 different proteins. The chips, which are based on BioMEMS technology, are designed to immobilize proteins on a surface while surrounding them in a hydrophilic environment.
The company has previously signed deals with Cambridge Antibody Technology (CAT) and Dyax for access to their antibody resources and technologies.
Cohen said Zyomyxs strategy is to form relationships with a variety of different antibody providers in order to maximize the content possibilities for its chips.
One of the most difficult things about protein chips as compared to DNA chips is the content, Cohen told BioArray News. You cant simply order an oligo. With CAT, Dyax, and BD Biosciences, a subsidiary of Becton Dickinson, there are strengths to each of their systems, he said. We expect to maximize them at this point.
The company earlier said it would launch its protein chips during the first half of this year, but Cohen said the companys plan is now to distribute a limited number of chips to academic and industry customers for beta testing in the fourth quarter.